- GSK invested €12m in a Kilo Scale Facility and Technical Development Laboratory at its Cork site.
- The Kilo Scale Facility will manufacture active ingredients for targeted oncology medicines.
- The Technical Development Laboratory will enhance the current product portfolio, including treatments for cancer, HIV, and depression.
- GSK has invested over €700m in the Cork site since 1974.
Investment and New Facilities
GSK has announced a €12m investment at its Currabinny-based manufacturing site in Cork, unveiling a €9.5m Kilo Scale Facility and a €2.5m Technical Development Laboratory. These facilities were inaugurated by Roger Connor, GSK’s Global Manufacturing Supply President, and Joe Power, GSK Cork Site Director.
Capabilities and Production
The Kilo Scale Facility will enable the site to manufacture highly specialized active ingredients for new, targeted oncology medicines. The Technical Development Laboratory will enhance the site's ability to improve its current product portfolio, which includes treatments for cancer, HIV, and depression.
Significance and Future Potential
Kevin O’Keefe, Head of Engineering at GSK Cork, highlighted that the new Kilo Scale Facility represents a significant opportunity for GSK in Cork, expanding the plant's operating scale to introduce new targeted medicines. Joe Power, Site Director, emphasized that this investment demonstrates GSK’s strong commitment to the Cork site and will attract new business while being rewarding for employees.
Historical Investment
Since its inception in 1974, GSK has invested over €700m in the Cork site. Last year alone, GSK invested €30m in R&D in Ireland, contributing significantly to the company’s global success in scientific innovation.
